The latest earnings reports indicate a strong performance for the S&P 500 in the fourth quarter, with 76% of companies surpassing earnings per share (EPS) estimates, slightly below the five-year average of 77% but above the ten-year average of 75%. The overall EPS growth for Q4 stands at 16.9%, the highest in three years, with nine out of eleven sectors reporting year-over-year earnings growth. In contrast, Glenmark Pharmaceuticals from India reported a third-quarter profit of ₹347.9 crore, recovering from a loss in the previous year, while GlaxoSmithKline Pharmaceuticals posted a 402% year-on-year increase in consolidated net profit to ₹228.58 crore, driven by strong demand for respiratory drugs and antibiotics. Additionally, 62% of S&P 500 companies have beaten revenue estimates, which is below both the five-year average of 69% and the ten-year average of 64%. The earnings landscape shows a mixed picture, with mid-cap firms outperforming while small caps have struggled.